

VIA EFS

Date of Deposit: February 19, 2009

Attorney Docket No. 24024-513 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Hasson, *et al.*

SERIAL NUMBER: 10/564,760

EXAMINER: Lora Elizabeth Barnhart

FILING DATE: July 7, 2006

ART UNIT: 1651

FOR: Ex Vivo Progenitor and Stem Cell Expansion for Use in the Treatment of  
Disease of Endodermally-Derived Organs

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


RESPONSE TO OFFICE COMMUNICATION

This is in response to the Office Communication dated February 13, 2009. A response is due on or before March 13, 2009. According to the Examiner, Applicants have not fully complied with the Restriction Requirement dated September 9, 2008, as Applicants' amendment to claim 50 necessitates an election of a single liver or pancreatic disease. *See*, Office Communication at page 2.

In response to the Office Communication, Applicants elect "diabetes" for the disorder. Claims 24-41, 47, 48, and 50-53 read on the elected species.

Applicants believe no fees are due. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-513 NATL. Should there be any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Matthew Pavao, Reg. No. 50,572  
Attorneys for Applicants  
c/o MINTZ LEVIN  
Customer No.: 30623  
Tel.: (617) 542-6000  
Fax: (617) 542-2241

Dated: February 19, 2009